Advertisement for orthosearch.org.uk
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

RECONSTRUCTION OF MASSIVE BONE LOSS DUE TO PERIPROSTHETIC INFECTION USING PROXIMAL FEMORAL ALLOGRAFT-PROSTHESIS COMPOSITES (APC)



Abstract

Aim: The purpose of our study is to present the survival results, clinical outcome and complications from the use of APC in cases with a history of periprosthetic infection.

Materials and Methods: Between 1986 and 1999, twenty-two patients (twenty-two hips) 11 male and 11 female (mean age 57.5 years – range 38 to 77 years) with massive bone loss (Paprosky IIIA 2 cases, IIIB 4 cases, and IV 16 cases) were included to our study. They all had a history of periprosthetic infection after an average of 3.3 (range 1 to 5) revision hip arthroplasties and were submitted to a two stage revision arthroplasty using an allograft-prosthesis composite.

Results: At an average follow-up of eleven years (range, eight to twenty years), 14 patients were alive, 7 patients died, and 1 patient was lost to follow-up. The ten year survival of the allograft-prosthesis composites was 74.9 per cent (95 per cent confidence interval 55.1 to 94.7 per cent, 4 cases remaining at risk). Seven cases presented with APC failure needing re-revision, 2 due to re-infection (4 and 23 months from revision by the same microorganism species as for the initial infection (Staph aureus to both cases), 3 due to allograft non union (at 21, 43, 79 months) and 2 cases due to graft resorption (164, 175 months post revision). Delayed healing and wound drainage occurred to 2 more cases.

Conclusion: Reconstruction of massive proximal femoral bone loss with an allograft-implant composite is a demanding procedure. Biologic means of reconstruction is a major advantage preserving bone stock for future surgery. However, high complication rate should be considered.

Correspondence should be addressed to: EFORT Central Office, Technoparkstrasse 1, CH – 8005 Zürich, Switzerland. Tel: +41 44 448 44 00; Email: office@efort.org

Author: George Babis, Greece

E-mail: george.babis@gmail.com